+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acid Sphingomyelinase Deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4845151
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 125 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

‘Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ASMDs in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acid sphingomyelinase deficiency (ASMD) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)
Study Period:2017-2028

Acid sphingomyelinase deficiency (ASMD) - Disease Understanding and Treatment Algorithm

Acid sphingomyelinase deficiency (ASMD) is a rare progressive genetic disorder that results from a deficiency of the enzyme acid sphingomyelinase, which is required to break down (metabolize) a fatty substance (lipid) called sphingomyelin and inherited in an autosomal recessive pattern. Acid sphingomyelinase, E.C. 3.1.4.12, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine. It is also known as Niemann-Pick disease.

The Acid sphingomyelinase deficiency (ASMD) market report gives the thorough understanding of the Acid sphingomyelinase deficiency by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acid sphingomyelinase deficiency in Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Acid sphingomyelinase deficiency Epidemiology

The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations) scenario of Acid sphingomyelinase deficiency (ASMD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

According to this report, the total number of prevalent cases of Acid sphingomyelinase deficiency (ASMD) in 10 EM was found to be 8,799, in the year 2017.

Acid sphingomyelinase deficiency Drug Chapters

This segment of the Acid sphingomyelinase deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment scenario in emerging markets is more or less same as in the United States and Europe. There is a tremendous lack of effective supportive therapies (especially for the infantile cases), let alone curative ones with the severe infantile neurovisceral phenotype encountering death by 3 years of age. Although the other less severe forms have a normal lifespan but a certain section die prematurely due to respiratory insufficiency and liver disease. Statins form the mainstay of treatment regimen used to treat hyperlipidemia characterized by low high-density lipoprotein (HDL) cholesterol in NPD Type B adult cases.

Acid sphingomyelinase deficiency Market Outlook

The Acid sphingomyelinase deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this report, the market of Acid sphingomyelinase deficiency in 10EM was found to be USD 1.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Acid sphingomyelinase deficiency, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Acid sphingomyelinase deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acid sphingomyelinase deficiency Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Acid sphingomyelinase deficiency Report Key Strengths
  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Acid sphingomyelinase deficiency Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Acid sphingomyelinase deficiency market
  • Organize sales and marketing efforts by identifying the best opportunities for Acid sphingomyelinase deficiency market
  • To understand the future market competition in the Acid sphingomyelinase deficiency market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1. Key Insights

2. Acid sphingomyelinase deficiency Market Overview at a Glance
2.1. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2017
2.2. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. History
3.3. Sub-types
3.3.1. NPD-A
3.3.2. NPD-B
3.4. Etiology of ASMD
3.5. Sign and Symptoms
3.6. Pathophysiology of ASMD
3.7. Diagnosis
3.7.1. Based on Chronic Visceral and Non-visceral ASMD
3.7.2. Based on Other Diseases
3.8. Biomarkers

4. Epidemiology and Patient Population - By Region
4.1. Key Findings
4.2. KOL Views

5. Ten Emerging Markets (EM) Total Prevalent Patient Population of Acid sphingomyelinase deficiency (ASMD)
5.1. Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets
5.2. Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets

6. Country Wise-Epidemiology of Acid sphingomyelinase deficiency (ASMD)
6.1. Emerging Markets: Assumptions and Rationale
6.2. China
6.2.1. Total Prevalent Cases of ASMD in China
6.2.2. Diagnosed Cases of ASMD in China
6.2.3. Diagnosed Cases of ASMD by clinical phenotype in China
6.2.4. Diagnosed Cases of ASMD based on clinical manifestations in China
6.3. Taiwan
6.3.1. Total Prevalent Cases of ASMD in Taiwan
6.3.2. Diagnosed Cases of ASMD in Taiwan
6.3.3. Diagnosed Cases of ASMD by clinical phenotype in Taiwan
6.3.4. Diagnosed Cases of ASMD based on clinical manifestations in Taiwan
6.4. Saudi Arabia
6.4.1. Total Prevalent Cases of ASMD in Saudi Arabia
6.4.2. Diagnosed Cases of ASMD in Saudi Arabia
6.4.3. Diagnosed Cases of ASMD by clinical phenotype in Saudi Arabia
6.4.4. Diagnosed Cases of ASMD based on clinical manifestations in Saudi Arabia
6.5. U.A.E.
6.5.1. Total Prevalent Cases of ASMD in UAE
6.5.2. Diagnosed Cases of ASMD in UAE
6.5.3. Diagnosed Cases of ASMD by clinical phenotype in UAE
6.5.4. Diagnosed Cases of ASMD based on clinical manifestations in UAE
6.6. Russia
6.6.1. Total Prevalent Cases of ASMD in Russia
6.6.2. Diagnosed Cases of ASMD in Russia
6.6.3. Diagnosed Cases of ASMD by clinical phenotype in Russia
6.6.4. Diagnosed Cases of ASMD based on clinical manifestations in Russia
6.7. Turkey
6.7.1. Total Prevalent Cases of ASMD in Turkey
6.7.2. Diagnosed Cases of ASMD in Turkey
6.7.3. Diagnosed Cases of ASMD by clinical phenotype in Turkey
6.7.4. Diagnosed Cases of ASMD based on clinical manifestations in Turkey
6.8. Mexico
6.8.1. Total Prevalent Cases of ASMD in Mexico
6.8.2. Diagnosed Cases of ASMD in Mexico
6.8.3. Diagnosed Cases of ASMD by clinical phenotype in Mexico
6.8.4. Diagnosed Cases of ASMD based on clinical manifestations in Mexico
6.9. Brazil
6.9.1. Total Prevalent Cases of ASMD in Brazil
6.9.2. Diagnosed Cases of ASMD in Brazil
6.9.3. Diagnosed Cases of ASMD by clinical phenotype in Brazil
6.9.4. Diagnosed Cases of ASMD based on clinical manifestations in Brazil
6.10. Argentina
6.10.1. Total Prevalent Cases of ASMD in Argentina
6.10.2. Diagnosed Cases of ASMD in Argentina
6.10.3. Diagnosed Cases of ASMD by clinical phenotype in Argentina
6.10.4. Diagnosed Cases of ASMD based on clinical manifestations in Argentina
6.11. Colombia
6.12. Total Prevalent Cases of ASMD in Colombia
6.13. Diagnosed Cases of ASMD in Colombia
6.14. Diagnosed Cases of ASMD by clinical phenotype in Colombia
6.15. Diagnosed Cases of ASMD based on clinical manifestations in Colombia

7. Treatment and Management of Acid sphingomyelinase deficiency

8. Unmet Needs

9. Emerging Therapies
9.1. Olipudase Alfa: Sanofi
9.1.1. Product Description
9.1.2. Other development Activities
9.1.3. Clinical Development
9.1.4. Safety and Efficacy
9.1.5. Advantages and Disadvantages
9.1.6. Product Profile

10. Acid sphingomyelinase deficiency: 10 EM Analysis
10.1. Key Findings
10.2. KOL Views
10.3. Market Size of ASMD in 10 EM
10.3.1. Market Size of ASMD by Therapies

11. Market Outlook by Country
11.1. Emerging Markets: Market Outlook
11.2. China
11.2.1. Total Market Size of ASMD
11.2.2. Market Size of ASMD by Therapies
11.3. Taiwan
11.3.1. Total Market Size of ASMD
11.3.2. Market Size of ASMD by Therapies
11.4. Saudi Arabia
11.4.1. Total Market Size of ASMD
11.4.2. Market Size of ASMD by Therapies
11.5. U.A.E.
11.5.1. Total Market Size of ASMD
11.5.2. Market Size of ASMD by Therapies
11.6. Russia
11.6.1. Total Market Size of ASMD
11.6.2. Market Size of ASMD by Therapies
11.7. Turkey
11.7.1. Total Market Size of ASMD
11.7.2. Market Size of ASMD by Therapies
11.8. Mexico
11.8.1. Total Market Size of ASMD
11.8.2. Market Size of ASMD by Therapies
11.9. Brazil
11.9.1. Total Market Size of ASMD
11.9.2. Market Size of ASMD by Therapies
11.10. Argentina
11.10.1. Total Market Size of ASMD
11.10.2. Market Size of ASMD by Therapies
11.11. Colombia
11.11.1. Total Market Size of ASMD
11.11.2. Market Size of ASMD by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix
14.1. Report Methodology

15. Capabilities

16. Disclaimer

17. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll